NWBO News and Press, Northwest Biotherapeutics Inc.

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities PR Newswire Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md. , July 3, 2024 /PRNewswire/ -- No...

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property PR Newswire Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise ...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors PR Newswire BETHESDA, Md. , March 21, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® ...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification PR Newswire Accompanied by Broad Patent Coverage BETHESDA, Md. , F...

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma PR Newswire Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, Md. , Dec. 21, 2023 ...

Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...

Greif Inc. Class A (GEF) is expected to report $1.3 for Q4 2023 Skandinaviska Enskilda Banken - Class A (SVKEF) is expected to report for Q3 2023 Yellow Corporation (YELLQ) is expected to report for Q3 2023 Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Lakeland Industrie...